EFFECTS OF AMINO ACID PERITONEAL DIALYSATE IN MALNUTRISHED PERITONEAL DIALYSIS PATIENTS

Öz

-

Anahtar Kelimeler

• -

EFFECTS OF AMINO ACID PERITONEAL DIALYSATE IN MALNUTRISHED PERITONEAL DIALYSIS PATIENTS

Öz

Aim: Malnutrition is common in peritoneal dialysis (PD) patients and hypoalbuminemia is a predictor of poor outcomes in end-stage renal disease patients. Amino acid peritoneal dialysate (AAPD) is used to improve nutritional status in malnourished PD patients. In this study, we investigated effects of AAPD on nutritional parameters in hypoalbuminemic PD patients. Methods: Sixteen (10 male and 6 female) patients, mean age 53.3±11.5 years old (range 36 to 70 years), mean dialysis duration 40.1 ± 31.0 months (range 4 to 99 months) and with serum albumin ≤ 3.9 g/dL were included in the study. Baseline and after three months of AAPD usage, nutritional parameters including, serum albumin, semiquantitative method of subjective global assessment (SGA), normalized protein catabolic rate (n-PCR) and lean body mass (LBM) were compared to evaluate the effects of AAPD on nutritional parameters in PD patients. Results: Thirteen patients completed the study. AAPD was well tolerated. After treatment blood urea nitrogen (BUN), albumin, n-PCR levels and SGA value increased. Serum albumin levels increased in 11 of 13 (84%) patients. However HDL cholesterol and creatinine clearance (CCr) decreased after AAPD. Conclusion: Amino acid peritoneal dialysate is an effective agent to improve nutritional status in PD patients and it is well tolerated. This is the second report about AAPD treatment showing the decrease in HDL cholesterol as a side effect. The mechanism and the effect of decreased HDL cholesterol need to be investigated in PD patients in larger and long-term studies. Key words: Albumin, HDL cholesterol, malnutrition, nutritional assessment, peritoneal dialysis

Anahtar Kelimeler

• Albumin, HDL cholesterol, malnutrition, nutritional assessment, peritoneal dialysis

Kaynakça

1. Weekes EC, Elia M, Emery PW. The development, validation and reliability of a nutrition screening tool based on the recommendations of the British Association for Parenteral and Enteral Nutrition (BAPEN). Clin Nutr 2004;23: 1104-12
2. Lowrie EG. Chronic dialysis treatment: clinical out-come and related processes of care. Am J Kidney Dis 1994;24:255- 66
3. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group J Am Soc Nephrol 1996;7:198-207
4. McCusker FX, Teehan BP, Thorpe KE, Keshaviah PR, Churchill DN. How much peritoneal dialysis is required for maintenance of a good nutritional state? Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Kidney Int 1996;56:56-61
5. Kopple JD. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis 1994;24:1002-9
6. Young GA, Kopple JD, Lindholm B et al. Nutritional assessment of continuous ambulatory peritoneal dialysis patients. An international study. Am J Kidney Dis 1991;17:462-71
7. Detsky AS, McLaughlin JR, Baker JP et al. J Parenter Enteral Nutr 1987;11:8-13
8. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutritioninflammation score is correlated with morbidity and mortality in maintenance haemodialysis patients. Am J Kidney Dis 2001;38:1251-63

9. Jones M, Hagen T, Boyle CA, et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study. Am J Kidney Dis 1998;32:761-9
10. Faller B, Aparicio M, Faict D et al. Clinical evaluation of an optimized 1.1% amino-acid solution for peritoneal dialysis. Nephrol Dial Transplant 1995;10:1432-7
11. Misra M, Ashworth J, Reaveley DA, Muller B, Brown EA. Nutritional effects of amino acid dialysate (Nutrineal) in CAPD patients. Adv Perit Dial 1996;12: 311-4
12. Bergstrom J, Heimburger O, Lindholm B. Calculation of the protein equivalent of total nitrogen appearence from urea appearence. Which formulas should be used? Perit Dial Int 1998;18:467-73
13. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J. Are two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000;15:953-60
14. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 2001;16:36-40
15. Kopple JD, Bernard D, Messana J et al. Treatment of malnutrished CAPD patients with an amino acid based dialysate. Kidney Int 1995;47:1148-57
16. Li FK, Chan LY, Woo JC et al. A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 2003;42: 173-83
17. Shockley TR, Martis L, Tranaeus AP. New solutions for peritoneal dialysis in adult and pediatric patients. Perit Dial Int 1999;19:429-34
18. Chung SH, Stenvinkel P, Bergstrom J, Lindholm B. Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve? Perit Dial Int 2000;20: 57-67
19. Qamar IU, Secker D, Levin L et al. Effects of amino acid dialysis compared to dextrose dialysis in children on continuous cycling peritoneal dialysis. Perit Dial Int 1999;19:237-47
20. Misra M, Reaveley DA, Ashworth J et al. Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1997;17:279-86
21. Yang SY, Huang JW, Shih KY et al. Factors associated with increased plasma homocysteine in patients using an amino acid peritoneal dialysis fluid. Nephrol Dial Transplant 2005;20:161-6